In conclusion, this analysis reveals that patients with advanced NSCLC and a very high PD-L1 TPS of greater than or equal to 90% have significantly improved OS at three years of follow-up from first-line pembrolizumab or cemiplimab monotherapy compared with those with a PD-L1 TPS of 50% to 89%. Here, CD274 is linked to non-small cell lung carcinoma.